Agonistic Antibody Engineering Service

Immune cell functions are tightly regulated by co-inhibitory and co-stimulatory receptors expressed on immune cells. The antagonistic antibodies dominate antibody drug discovery to block negative immune checkpoints and reverse immune resistance of tumors and cancers. Agonistic antibodies have been regarded as promising immune therapeutic agents and a growing number of these agents are making their way through various stages of preclinical and clinical development.

With advanced technologies and years of experience in the antibody development field, Creative Biolabs offers specialized support in the discovery, screening, engineering, and characterization of agonistic antibodies targeting various co-stimulatory receptors.

Discovery, Screening, and Characterization of Agonistic Antibody

Agonistic antibodies are antibodies developed against co-stimulatory receptors, which are activated in response to foreign antigens. Due to their high specificity and high affinity, agonistic antibodies act like natural ligands to bind the receptor but mediate more potent downstream signaling. Several agonistic antibodies that target costimulatory molecules, such as CD27, CD40, OX40, 4‑1BB, GITR, ICOS and CD28, have been reported.

For agonistic antibody screening, we employ hybridoma technology coupled with function-based cellular screening assays or phage-display technology to identify potential agonist antibodies targeting a specific target. Besides, we offer agonistic antibody characterization services for clients to characterize the properties of the antibody candidates and to test the efficacy, including but not limited to:

Assessment of interaction of antibody crystallizable fragment (Fc) with Fcγ receptors (FcγRs)
Target binding assessment of Fab
T cell proliferation & cytokine production evaluation
Cytolytic effector function testing in vitro
Agonistic activity testing in vivo

Engineering of Agonistic Antibody

In the process of agonistic antibody development, antibody engineering is often required for improved agonistic potential and efficacy. For instance, because the ability of an antibody to induce receptor supercluster formation is critical for costimulatory agonist function, engineering for bispecific antibodies may be particularly useful in activating multicomponent receptor complexes. Besides, factors such as binding epitope, affinity, the interaction of Fc domain with FcγRs can also influence the propensity of an antibody to act as an agonist. At Creative Biolabs, we offer different engineering strategies to optimize the agonistic activity of your antibody, including but not limited to:

Engineering for biparatopic antibody (i.e. antibody targeting two different epitopes on the same target resulting in superior properties)
Engineering of agonistic monoclonal antibody into a variety of formats
Antibody humanization
Affinity maturation to improve the affinity of candidate antibodies for the target receptor
Antibody Fc engineering to increase the affinity of native IgGs for FcγRIIB
Aglycosylation of antibodies to avoid effector functions

Advantages of Our Services

Design and development of agonistic antibodies against different targets
A full set of in vitro and in vivo assays for testing the potency of the agonistic antibody candidates
Abundant experience with the successful discovery of agonist antibodies to a panel of receptors
Customized engineering strategies to suit specific applications

For more detailed information, please feel free to contact us or directly send us an online inquiry.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Online Inquiry

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: info@creative-biolabs.com